Thirona Retina acquired by Revenio Group
Today we have announced acquisition of Thirona Retina by Revenio Group Corporation’s subsidiary Icare Finland Oy. After years of [...]
RetCAD™ announces partnership with Optomed
We are happy to announce that Thirona Retina entered a partnership with Finnish medical technology company Optomed.
RetCAD enables DR screening for remote communities in Australia
Thirona Retina joined forces with Topcon Healthcare to provide on-spot eye screening solution among distant communities.
New impressive results of validation study with InHealth at 100% Optical
Thirona Retina visited 100% Optical conference in London, presenting amazing results of a recent study with InHealth Intelligence.
Thirona spins out the Retina business to pursue long-term growth plans
Thirona decided to spin out its Retina division into Thirona Retina BV. entirely dedicated to the eye diseases market
Another validation of RetCAD showing great performance for simultaneously screening for AMD and DR
RetCAD provided very impressive results when measuring it’s sensitivity and specificity with AMD and DR grading.
RetCAD™ 2.0 version approved for use in Australia and New Zealand
We are pleased to announce that the RetCAD™ 2.0 release has been approved for use by TGA, Australia's regulatory authority.
RetCAD™ patient report now available in 6 languages
The screening report can now be accessed in Dutch, German, Italian, Spanish, Finnish and English.
RetCAD's user experience further optimised with new screening report
RetCAD™ analysis is further optimised for clinical use
Thirona’s RetCAD™ certified with Class IIa European MDR
RetCAD™ software has been granted a Class IIa MDR CE certification.
Thirona closes financing round with HERAN Partners and Borski Fund
We are pleased to have found the right partners in HERAN Partners and Borski Fund.
International distribution partnership with NIDEK
We are pleased to announce our distribution partnership with Nidek CO., LTD.
Thirona is now compliant with the new Medical Device Regulation
Thirona successfully implemented the requirements and we are now certified against the new MDR.
RetCAD is cleared for clinical use in New Zealand
We look forward to working with our users in New Zealand.